Preoperative anti-inflammatory treatment of diabetic patients does not improve recovery from cataract surgery when postoperatively treated with a combination of prednisolone acetate and nepafenac.
Aged
Aged, 80 and over
Anti-Inflammatory Agents
/ administration & dosage
Benzeneacetamides
/ administration & dosage
Cataract Extraction
Diabetes Mellitus
/ drug therapy
Dose-Response Relationship, Drug
Drug Therapy, Combination
Female
Follow-Up Studies
Humans
Male
Middle Aged
Ophthalmic Solutions
Phenylacetates
/ administration & dosage
Postoperative Care
/ methods
Postoperative Complications
/ prevention & control
Prednisolone
/ administration & dosage
Preoperative Care
/ methods
Prospective Studies
Tomography, Optical Coherence
cataract surgery
diabetes
nonsteroidal anti-inflammatory drug
preoperative treatment
pseudophakic cystoid macular oedema
steroid
Journal
Acta ophthalmologica
ISSN: 1755-3768
Titre abrégé: Acta Ophthalmol
Pays: England
ID NLM: 101468102
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
12
08
2018
accepted:
26
10
2018
pubmed:
9
1
2019
medline:
4
9
2019
entrez:
9
1
2019
Statut:
ppublish
Résumé
To examine preoperative anti-inflammatory treatment on recovery from cataract surgery in eyes of diabetic patients. A Prospective randomized clinical trial. One hundred and three eyes of 103 patients with diabetes undergoing routine cataract surgery were randomized (1:1) not to receive any preoperative anti-inflammatory medication or to receive preoperative topical anti-inflammatory medication with a combination of prednisolone acetate (10 mg/ml) and nepafenac (1 mg/ml). All eyes received postoperative anti-inflammatory combination therapy for 3 weeks. Recovery from surgery was recorded by a structured home questionnaire. Clinical outcome parameters were recorded at 28 days and 3 months. Patient age and gender distribution, and all baseline ophthalmic and systemic parameters were comparable between the study groups. After surgery, conjunctival injection lasted 2.4 ± 1.7 days (mean ± SD) and irritation of the eye 3.3 ± 3.9 days in eyes without preoperative treatment, when compared to 1.6 ± 1.6 days (p = 0.067) and 2.4 ± 4.0 days (p = 0.431), respectively, in eyes with preoperative treatment. At 28 days, central subfield macular thickness (CSMT) increased 2.2 ± 20.2 μm in eyes without preoperative treatment, when compared 0.1 ± 25.2 μm (p = 0.670) in eyes with preoperative treatment. At 3 months, the respective CSMT change from baseline was -1.5 ± 26.9 μm and -3.4 ± 26.2 μm (p = 0.762). None of the eyes were reported with pseudophakic cystoid macular oedema (PCME) in either group. Lack of preoperative anti-inflammatory treatment does not impair recovery from surgery or predispose diabetic patients to increased risk of PCME in eyes postoperatively treated with combination therapy of prednisolone acetate and nepafenac.
Substances chimiques
Anti-Inflammatory Agents
0
Benzeneacetamides
0
Ophthalmic Solutions
0
Phenylacetates
0
nepafenac
0J9L7J6V8C
prednisolone acetate
8B2807733D
Prednisolone
9PHQ9Y1OLM
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
589-595Subventions
Organisme : Finnish Eye Foundation
Organisme : Finnish Ophthalmological Society
Organisme : Nissi Foundation
Organisme : Paulo Foundation
Organisme : Waldemar von Frenckell Foundation
Organisme : HUS Specific Catchment Area (ERVA) Clinical Research Grants
Organisme : Finnish Medical Foundation
Informations de copyright
© 2019 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.